UCB Announces Start of Phase III Program with Epratuzumab for Patients with Moderate to Severe SLE

Brussels, and Morris Plains, New Jersey - regulated information - UCB (EURONEXT: UCB) and U.S. based partner Immunomedics Inc. (NASDAQ: IMMU) today announced the enrollment of the first patient into EMBODY™ 1, one of two pivotal phase III studies of epratuzumab in patients with moderate to severe systemic lupus erythematosus (SLE). Patient enrollment for EMBODY™ 2 has also begun.

Full story